Akari Therapeutics PLC Cash Flow Conversion Efficiency
Akari Therapeutics PLC cash flow conversion efficiency. Based on the latest financial reports, Akari Therapeutics PLC (AKTX) has a cash flow conversion efficiency ratio of -0.107x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.04 Million) by net assets ($28.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Akari Therapeutics PLC (2010–2025)
Cash flow conversion efficiency of Akari Therapeutics PLC from 2010 to 2025. This chart illustrates how Akari Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Akari Therapeutics PLC stock price today for real-time trading data and today's change.
Akari Therapeutics PLC Cash Flow Conversion Ratio Explained
Akari Therapeutics PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Akari Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akari Therapeutics PLC ranked by their cash flow conversion efficiency. Also see how much is Akari Therapeutics PLC worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aeris Environmental Ltd
AU:AEI
|
0.354x |
|
Avrasya Petrol ve Turistik Tesisler Yatirimlar AS
IS:AVTUR
|
0.010x |
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
-0.192x |
|
Funding Circle Holdings PLC
LSE:FCH
|
-0.215x |
|
Pacific Nickel Mines Ltd
AU:PNM
|
-1.186x |
|
Pembangunan Graha Lestari Tbk
JK:PGLI
|
0.016x |
|
Postmedia Network Canada Corp
TO:PNC-B
|
-0.023x |
|
Compass Group PLC
LSE:CPG
|
0.258x |
Annual Cash Flow Conversion Efficiency for Akari Therapeutics PLC (2010–2025)
The table below shows the annual cash flow conversion efficiency of Akari Therapeutics PLC from 2010 to 2025. Review AKTX free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $28.33 Million | $-10.57 Million | -0.373x | +33.93% |
| 2024-12-31 | $22.23 Million | $-12.55 Million | -0.565x | -100.79% |
| 2023-12-31 | $-229.00K | $-16.43 Million | 71.755x | +697.63% |
| 2022-12-31 | $1.79 Million | $-21.50 Million | -12.007x | -253.87% |
| 2021-12-31 | $5.55 Million | $-18.85 Million | -3.393x | -87.85% |
| 2020-12-31 | $9.38 Million | $-16.95 Million | -1.806x | +46.36% |
| 2019-12-31 | $3.84 Million | $-12.92 Million | -3.368x | -99.88% |
| 2018-12-31 | $13.38 Million | $-22.54 Million | -1.685x | -6.53% |
| 2017-12-31 | $19.98 Million | $-31.60 Million | -1.582x | -119.04% |
| 2016-12-31 | $34.10 Million | $-24.62 Million | -0.722x | -608.46% |
| 2015-12-31 | $48.72 Million | $-4.97 Million | -0.102x | +94.77% |
| 2014-12-31 | $4.85 Million | $-9.46 Million | -1.950x | -107.97% |
| 2013-12-31 | $5.81 Million | $-5.45 Million | -0.937x | -247.59% |
| 2012-12-31 | $-3.36 Million | $-2.13 Million | 0.635x | +56.57% |
| 2011-12-31 | $-2.48 Million | $-1.01 Million | 0.406x | +124.84% |
| 2010-12-31 | $-2.03 Million | $-366.00K | 0.180x | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more